GBX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Greenbrier Companies Inc (GBX) is not a strong buy for a beginner long-term investor at this time. Despite some positive technical indicators, the company's weak financial performance, mixed analyst ratings, and lack of significant positive catalysts suggest that holding off on investment may be prudent. The stock's overbought RSI and potential for short-term declines further support this conclusion.
The technical indicators show mixed signals. The MACD histogram is positive and expanding, suggesting bullish momentum. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key resistance levels. However, the RSI_6 is at 86.167, indicating the stock is overbought, which could lead to a short-term pullback. Additionally, candlestick pattern analysis suggests a 60% chance of a decline in the next day (-1.42%), week (-1.54%), and month (-4.3%).
The MACD and moving averages indicate bullish momentum. Analysts have raised price targets recently, with Susquehanna increasing its target to $60 and maintaining a Positive rating.
The RSI indicates overbought conditions, suggesting a potential pullback. Financial performance in Q1 2026 was weak, with revenue down 19.39% YoY, net income down 34.18% YoY, and EPS down 33.72% YoY. Analyst ratings are mixed, with Goldman Sachs maintaining a Sell rating and citing industry headwinds. No significant news or trading trends from hedge funds, insiders, or Congress have been reported.
In Q1 2026, the company reported a significant decline in financial metrics: revenue dropped by 19.39% YoY to $706.1 million, net income fell by 34.18% YoY to $36.4 million, EPS decreased by 33.72% YoY to $1.14, and gross margin dropped by 26.19% YoY to 14.63%. These figures indicate a challenging financial environment for the company.
Analyst ratings are mixed. Susquehanna raised its price target to $60 and maintained a Positive rating, citing stable railcar demand and international momentum. However, BofA raised its target to $49 but kept an Underperform rating, highlighting core results that missed expectations. Goldman Sachs initiated coverage with a Sell rating and a $38 price target, citing industry cyclicality and potential medium-term headwinds.
